Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in Japanese Patients With Indolent B-cell NHL
NCT02342665Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in B-cell non-Hodgkin lymphoma, sponsored by Bayer. Primary endpoints: Number of participants with Adverse Events up to 18 months, Intensity of Adverse Events up to 18 months and 2 more. Started Apr 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02342665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342665.